冠心病患者经皮冠状动脉介入术治疗后血浆IL-12、MCP-1的水平变化

doi:10.3969/j.issn.1671-7171.2017.01.022

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the changes of plasma IL-12 and MCP-1 for patients with coronary artery after percutaneous coronary intervention, and the correlation with short-term prognosis. 【Methods】Clinical data of 268 patients with CHD from January 2013 to December 2015 in our hospital were set as the observation group, and 50 healthy volunteers underwent coronary angiography with normal coronary arteries were selected in the same period of time in our hospital as the control group. The plasma levels of IL-12 and MCP-1 were compared between the two groups. The incidence of adverse cardiovascular events in CHD patients was observed, and the correlation between IL-12 and MCP-1 levels and adverse cardiovascular events were analyzed.【Results】Before surgery, plasma IL-12, MCP-1 levels in observation group were significantly higher than those of the control group, the difference was significant (mean P <0.05); After surgical treatment of PCI, a significant decrease in the above levels were found in the observation group, the difference was significant (mean P<0.05), while there was no significant difference before and after angiography in the control group, the difference was not statistically significant(mean P＞0.05); Plasma IL-12 and MCP-1 levels were positively correlated with major adverse cardiovascular events (mean P<0.05). 【Conclusion】Plasma IL-12 and MCP-1 levels were significantly lower in patients with CHD after PCI; this could be correlative with the short term adverse prognosis of patients with CHD.

Key words： Coronary Disease Angioplasty, Transluminal, Percutaneous Coronary Interleukin-12/BL Chemokine CCL2/BI

Received: 24 November 2016

PACS:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2017.01.022 OR http://www.jcr.net.cn/EN/Y2017/V34/I1/67

[1] Cirillo P,Cimmino G,D'Aiuto E,et al. Local cytokine production in patients with Acute Coronary Syndromes:a look into the eye of the perfect (cytokine) storm[J].Int J Cardiol,2014,176(1):227-229.
[2] 周选民,刘梅讯,李小力,等. 急性冠脉综合征患者接受经皮冠脉介入治疗后血浆 IL-12 水平变化及相关性分析[J].中国医药导报, 2016,13(16):19-22.
[3] 王晓丽, 刘丽军, 信栓力, 等. 冠状动脉介入治疗对冠心病患者血浆MMP-9和IL-6水平的影响[J].中西医结合心脑血管病杂志, 2013,11(12):1435-1436.
[4] O'Donoghue ML. Acute coronary syndromes:targeting inflammation-what has the VISTA-16 trial taught us [J]?Nat Rev Cardiol,2014,11(3):130-132.
[5] Novo G,Bellia C,Fiore M,et al. A risk score derived from the analysis of a cluster of 27 serum inflammatory cytokines to predict long term outcome in patients with acute myocardial infarction:a pilot study [J].Ann Clin Lab Sci,2015, 45(4): 382-390.
[6] Trpkovic A,Resanovic I,Stanimirovic J,et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases [J].Crit Rev Clin Lab Sci,2015,52(2):70-85.
[7] Martínez GJ,Robertson S,Barraclough J,et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome [J].J Am Heart Assoc,2015,4(8):e002128.
[8] 陈广琴, 王强, 曲楠, 等. 急性冠脉综合征支架置入术后血MCP-1、1IL-10和hs-CPR水平的改变与瑞舒伐他汀的干预作用[J].广西医科大学学报,2011,28(5):723-725.
[9] 胡章乐, 王晓晨, 许邦龙, 等. 经皮冠状动脉介入治疗对不稳定心绞痛患者血浆MMP-9、CRP、IL-18及CTnI的影响和意义[J].临床与病理杂志,2015, 35(7):1351-1355.
[10] 齐晓勇, 谷剑, 李树仁,等. 冠心病患者介入治疗前后血浆白细胞介素-8变化与早期并发症的关系[J].临床心血管病杂志, 2004, 20(6):334-336.
[11] 刘丽军, 信栓力, 常超,等. 冠心病心绞痛患者血浆白细胞介素-6和单核细胞趋化因子-1变化及其临床意义[J]. 疑难病杂志, 2013, 12(3):172-174.
[12] 马江伟, 乔增勇, 张立,等. 阿托伐他汀与瑞舒伐他汀对冠状动脉内支架植入术后MCP-1、IL-10及其比值的影响[J].中华临床医师杂志:电子版, 2010, 4(12):104-107.
[13] 贾兴旺, 田亚平, 郭广宏. 血清12项细胞因子在冠心病诊断中的应用价值[J].中华检验医学杂志, 2006, 29(9):830-833.
[14] Maseri A. Inflammation,atherosclerosis,and ischemic eventsexploring the hidden side of the moon [J].N Engl J Med,1997,336(14):1014-1016.